Outcome of the Meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Limited held on Today i.e. Thursday, 12th February, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Welcure Drugs & Pharmaceuticals approved the unaudited financial results for the quarter and nine months ended 31st December 2025. Revenue from operations for 9M FY26 surged to about Rs 36,700 lakhs compared to Rs 2,455 lakhs in 9M FY25, driven almost entirely by a new 'Agriculture' segment. Net profit for 9M FY26 jumped to Rs 4,340 lakhs versus Rs 96 lakhs a year earlier, though the standalone Q3 (Oct-Dec 2025) showed zero revenue from operations and only Rs 107 lakhs profit. Segment data confirms a full pivot from Drugs & Pharmaceuticals to Agriculture as the dominant business. Shareholders' funds expanded sharply as paid-up equity capital grew from Rs 1,125 lakhs to Rs 12,359 lakhs, indicating a major share issuance during the year. The statutory auditor issued a limited review report with multiple caveats, flagging reliance on management-provided data for debtors, creditors, investments, deposits, and loans, and did not express an opinion on the statements.
The headline numbers look dramatic, but the heavy reliance on a new Agriculture segment, the Q3 revenue collapse to zero, the ~10x jump in share capital, and the auditor's disclaimer of opinion are major red flags. Retail investors should treat these results with caution and wait for the full audited accounts and clarity on the business shift before drawing conclusions.